BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26567007)

  • 1. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.
    Murdaca G; Contini P; Cagnati P; Marenco S; Pieri G; Lantieri F; Picciotto A; Puppo F
    Clin Exp Med; 2017 Feb; 17(1):93-100. PubMed ID: 26567007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
    Veillon P; Fouchard-Hubert I; Larrey D; Dao MT; D'alteroche L; Boyer-Darrigand N; Picard N; Le Guillou-Guillemette H; Saulnier P; Ducancelle A; Loustaud-Ratti V; Lunel-Fabiani F
    J Interferon Cytokine Res; 2016 Mar; 36(3):204-14. PubMed ID: 26700738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
    Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
    Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.
    Guzmán-Fulgencio M; Berenguer J; Rallón N; Fernández-Rodríguez A; Miralles P; Soriano V; Jiménez-Sousa MA; Cosín J; Medrano J; García-Álvarez M; López JC; Benito JM; Resino S
    AIDS; 2013 May; 27(8):1231-8. PubMed ID: 23811951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
    Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
    Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Moreno L; Quereda C; Moreno A; Perez-Elías MJ; Antela A; Casado JL; Dronda F; Mateos ML; Bárcena R; Moreno S
    AIDS; 2004 Jan; 18(1):67-73. PubMed ID: 15090831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
    Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G
    New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
    Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
    J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
    Marchetti G; Nasta P; Bai F; Gatti F; Bellistrì GM; Tincati C; Borghi F; Carosi G; Puoti M; Monforte Ad
    PLoS One; 2012; 7(2):e32028. PubMed ID: 22363790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between
    Yao Y; Liu M; Zang F; Yue M; Xia X; Feng Y; Fan H; Zhang Y; Huang P; Yu R
    BMJ Open; 2018 Apr; 8(4):e019406. PubMed ID: 29654010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.